Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Trinity Biotech (TRIB) Accumulated Expenses (2016 - 2025)

Trinity Biotech's Accumulated Expenses history spans 7 years, with the latest figure at $16.9 million for Q4 2025.

On a quarterly basis, Accumulated Expenses rose 24.53% to $16.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.9 million, a 24.53% increase, with the full-year FY2025 number at $16.9 million, up 24.53% from a year prior.
Accumulated Expenses hit $16.9 million in Q4 2025 for Trinity Biotech, up from $13.6 million in the prior quarter.
Over the last five years, Accumulated Expenses for TRIB hit a ceiling of $16.9 million in Q4 2025 and a floor of $13.6 million in Q4 2024.